Please assess the completion status of the following clinical trial:

Trial Title: LY231514 Plus Gemcitabine in Treating Women With Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically or cytologically confirmed breast cancer with clinical evidence of metastatic disease~* Bidimensionally measurable disease~  * If bisphosphonates used, must have measurable disease site other than bone~ * No bone only disease~* Must have received a prior anthracycline and taxane in the adjuvant and/or metastatic setting~* No clinically significant pericardial effusions, pleural effusions, or ascites unless they can be drained~* No active CNS metastases~  * Treated CNS metastasis that has ben stable for at least 8 weeks allowed~* Hormone receptor status:~  * Not specified~PATIENT CHARACTERISTICS:~Age:~* 18 and over~Sex:~* Female~Menopausal status:~* Not specified~Performance status:~* ECOG 0-2~Life expectancy:~* At least 3 months~Hematopoietic:~* Absolute neutrophil count at least 1,500/mm\^3~* Platelet count at least 100,000/mm\^3~Hepatic:~* Bilirubin no greater than 2 times upper limit of normal (ULN)~* AST no greater than 3 times ULN (5 times ULN if liver metastases)~* Albumin at least 3.0 g/dL~Renal:~* Creatinine clearance at least 45 mL/min~Cardiovascular:~* No New York Heart Association class III or IV heart disease~Other:~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* Able to take folic acid and cyanocobalamin (vitamin B12) supplements~* Body surface area less than 3 m\^2~* No uncontrolled infection~* No chronic debilitating disease~* No other prior malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer or adequately treated noninvasive carcinomas~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* At least 4 weeks since prior immunotherapy~* At least 4 weeks since prior genetic therapy~* No concurrent immunomodulating agents~Chemotherapy:~* See Disease Characteristics~* No more than 3 prior chemotherapy regimens including adjuvant therapy~  * No more than 1 prior chemotherapy regimen for metastatic disease unless these were a taxane and anthracycline~* At least 4 weeks since prior chemotherapy~* No prior gemcitabine and/or pemetrexed disodium~* No other concurrent cytostatic or cytotoxic chemotherapy~Endocrine therapy:~* Not specified~Radiotherapy:~* At least 4 weeks since prior radiotherapy~* No prior radiotherapy to greater than 25% of bone marrow~* No prior strontium chloride Sr 89~* No concurrent radiotherapy~Surgery:~* At least 4 weeks since prior major surgery~Other:~* No aspirin or nonsteroidal antiinflammatory agents 2 days before, the day of, and for 2 days after pemetrexed disodium administration (5 days before for long acting agents such as naproxen, piroxicam, diflunisal, or nabumetone)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- gemcitabine + pemetrexed (Type: EXPERIMENTAL): Patients receive gemcitabine IV over 30 minutes on days 1 and 8. pemetrexed disodium IV is administered over 10 minutes 90 minutes following gemcitabine on day 8. Treatment continues every 21 days for a minimum of 6 courses in the absence of unacceptable toxicity or disease progression. Patients achieving a complete response receive 2 additional courses.~Patients are followed every 3 months for 5 years.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete